The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

The present disclosure provides a method for diagnosing cancer, assessing cancer prognosis, monitoring cancer, or assessing effectiveness of cancer treatment. The present disclosure also provides a method for diagnosing cancer, assessing cancer prognosis, monitoring cancer, or assessing effectiveness of cancer treatment by using an atypical circulating tumor cell.

The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

An apparatus for isolating stems cells from extracted mammalian tissue comprising: a portable hollow casing having fixed dimensions and a sized internal spatial volume; a filter housed and contained within said sized internal spatial volume, wherein said filter captures particles in said extracted mammalian tissue having a diameter of about 5 to 10 microns or more and allows particles in said extracted mammalian tissue having a diameter of less than about 5 to 10 microns to pass through; a first channel to which a container holding said extracted mammalian tissue can attach, and through which said extracted mammalian tissue is input into the hollow casing; wherein a stem cell collection chamber can attach to said first channel, and the particles having a diameter of about 5 to 10 microns or more are output from the hollow casing through said first channel and collected in the stem cell collection chamber; and a second channel to which a remnant collection chamber can attach, and through which the particles having a diameter of less than about 5 to 10 microns are output from the hollow casing and collected in the remnant collection chamber.

Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.

The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

Blood from a blood source is drawn into a fluid flow circuit. A mononuclear cell product is separated from the blood, followed by at least a portion of the mononuclear cell product being conveyed into an electroporation device without disconnecting the blood source from the fluid flow circuit. The electroporation device opens pores in a membrane of at least one of the cells of the mononuclear cell product to allow DNA material (which is added to the mononuclear cell product prior to electroporation) to enter and modify the genome of the cell. At least a portion of the modified mononuclear cell product is returned to the blood source. The mononuclear cell product may be washed prior to being conveyed into the electroporation device. The modified mononuclear cell product may be washed after exiting the electroporation device.

Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.

Methods of expanding a natural killer (NK) cell fraction for transplantation into a subject are provided, and particularly, methods for providing transplantable NK cell fractions and protocols for their use, which can be employed for applications in cell transplants and infusions for treatment of cancer and other disease.

The invention relates to method for the separation of cord blood endothelial cells from hematopoietic cells in a manner that preserves the hematopoietic cells' repopulating ability and primitivity, without significantly reducing the yield of hematopoietic cells. The said endothelial cells from cord blood have a utility in cell based therapeutics. The system described takes advantage of the endogenous adherence properties of the cells to facilitate the separation and separate storage of the cell types.